Press Releases

Date Title
03/19/19
Summary TogglePulse Biosciences Appoints Mitchell Levinson to Board of Directors
03/15/19
Summary TogglePulse Biosciences Grants Equity Incentive Awards to New Employees
03/01/19
Summary TogglePulse Biosciences Announces Late Breaking Oral Presentation of Sebaceous Hyperplasia Study Results at the 2019 AAD Annual Meeting
02/28/19
Summary TogglePulse Biosciences Submits 510(K) to U.S. FDA for CellFX™ System
02/15/19
Summary TogglePulse Biosciences Grants Equity Incentive Awards to New Employees
02/07/19
Summary TogglePulse Biosciences Quarterly Investor Conference Call
01/28/19
Summary TogglePulse Biosciences to Report Fourth Quarter and Full Year 2018 Operational Highlights and Financial Results
01/17/19
Summary TogglePulse Biosciences Announces Two Appointments Focused on CellFX™ Commercialization: Promotion of Edward Ebbers and Addition of Robert Tyson
01/15/19
Summary TogglePulse Biosciences Grants Equity Incentive Awards to New Employees
01/07/19
Summary TogglePulse Biosciences Announces Positive Clinical Results of Its Nano-Pulse Stimulation™ Technology Platform to Treat Patients with Sebaceous Hyperplasia Lesions on the Face
12/17/18
Summary TogglePulse Biosciences Grants Equity Incentive Awards to New Employees
12/14/18
Summary TogglePulse Biosciences, Inc. Announces Closing of Its $45 Million Rights Offering
12/07/18
Summary TogglePulse Biosciences, Inc. Announces Oversubscription, Pricing and Preliminary Results for Its $45 Million Rights Offering
11/19/18
Summary TogglePulse Biosciences, Inc. Announces Commencement of Rights Offering
11/15/18
Summary TogglePulse Biosciences Grants Equity Incentive Awards to New Employees